Updated

Updated · The Hastings Center · Jun 24

Supreme Court to Hear Louisiana Challenge to Mailed Abortion Pills in 13 Ban States

Updated

Updated · The Hastings Center · Jun 24

Supreme Court to Hear Louisiana Challenge to Mailed Abortion Pills in 13 Ban States

Q: If science confirms the pill's safety, what legal argument could still restrict mail-order access nationwide?

Yes. Even if the medical evidence remains strong, mail-order access could still be restricted on legal grounds unrelated to safety. The most important argument is the Comstock Act, an 1873 federal law that opponents say bars mailing drugs intended for abortion. If the Supreme Court accepts that reading, the FDA’s judgment that mifepristone is safe would not by itself protect nationwide shipment. A second route is administrative law. Louisiana argues the FDA violated the Administrative Procedure Act when it removed the in-person dispensing requirement and allowed certified pharmacies to mail the drug. Under that theory, a court could restore older restrictions because of how the agency acted, not because the pill is unsafe. The case also raises a federal-state power dispute. Louisiana says mail-order mifepristone interferes with its abortion ban and imposes state costs when patients seek follow-up care. That argument is aimed at establishing legal standing and defending state authority after *Dobbs*, rather than disputing the core scientific record. That is why reproductive-rights advocates worry science alone may not decide the case. The Supreme Court’s earlier mifepristone ruling turned on standing, not safety. In *Louisiana v. FDA*, the central question may again be legal authority: whether the FDA’s rules, federal mailing law, or state abortion restrictions control access to pills sent through the mail.

3 articles · Updated · The Hastings Center · Jun 24

Louisiana v. FDA will put the legal status of mailed mifepristone before the Supreme Court, with a decision expected next year and major implications for abortion access in states that ban the procedure.
Louisiana argues the FDA should not allow mail-order abortion pills, and a New Orleans appeals court backed the state after its attorney general said Louisiana pays thousands of dollars in Medicaid costs for women harmed by mifepristone.
The case follows a similar Supreme Court ruling just two years ago, when the justices unanimously rejected antiabortion doctors' challenge to FDA rules because they lacked legal standing to sue.
Medication abortion has become the main abortion method nationwide and, in the 13 states with total bans, often the last potentially available way to end a pregnancy, making any new restriction on mailed pills especially consequential.

Sources

Left80%

Center20%

The Hastings Center21h ago

Supreme Court to Hear Louisiana v. FDA on Mailed Abortion Pills

NPR21h ago

How abortion in America has changed since the Dobbs decision : NPR

The Leaven.com1d ago

USCCB and pro-life leaders: Abortion pills remain key post-Dobbs challenge - The Leaven Catholic Newspaper

9 Sources

If science confirms the pill's safety, what legal argument could still restrict mail-order access nationwide?

If mifepristone is restricted, could another widely available pill become the new standard for medication abortion?

Why might a state's claim of financial harm succeed in court when a doctor's claim of injury failed?

Louisiana v. FDA and the Fight Over Mifepristone: How Legal Challenges Threaten Abortion Access and FDA Authority Nationwide

Overview

The ongoing case of Louisiana v. FDA highlights a pivotal moment for abortion access in the U.S. The FDA, as the main defendant, has chosen not to defend its decision to allow mifepristone to be mailed, a move seen as a political strategy to avoid controversy. Louisiana, confident in its position, points out that both lower courts agree it is likely to win, arguing the FDA broke federal rules by permitting mail delivery of the medication. If the courts side with Louisiana, in-person dispensing could return, reshaping how medication abortion is accessed and regulated nationwide.

...